Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis-Reference-Cited by-同舟云学术

Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis

Published:2020-02-01 Issue:2 Volume:156 Page:131
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Worm Margitta¹,Simpson Eric L.²,Thaçi Diamant³,Bissonnette Robert⁴,Lacour Jean-Philippe⁵,Beissert Stefan⁶,Kawashima Makoto⁷,Ferrándiz Carlos⁸,Smith Catherine H.⁹,Beck Lisa A.¹⁰,Chan Kuo-Chen¹¹,Chen Zhen¹¹,Akinlade Bolanle¹¹,Hultsch Thomas¹²,Staudinger Heribert¹³,Gadkari Abhijit¹¹,Eckert Laurent¹⁴,Davis John D.¹¹,Rajadhyaksha Manoj¹¹,Graham Neil M. H.¹¹,Pirozzi Gianluca¹³,Stahl Neil¹¹,Yancopoulos George D.¹¹,Ardeleanu Marius¹¹

Affiliation:

1. Division of Allergy and Immunology, Klinik für Dermatologie, Venerologie und Allergologie, Charité–Universitätsmedizin Berlin, Berlin, Germany

2. Department of Dermatology, Oregon Health & Science University, Portland

3. Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany

4. Innovaderm Research, Montreal, Quebec, Canada

5. Department of Dermatology, Nice University Hospital, Nice, France

6. Klinik und Poliklinik für Dermatologie, Universitätsklinikum, Technische Universität Dresden, Dresden, Germany

7. Tokyo Women's Medical University, School of Medicine, Tokyo, Japan

8. Servicio de Dermatología, Hospital Universitario Germans Trias i Pujol, Universidad Autónoma de Barcelona, Badalona, Spain

9. St John's Institute of Dermatology, Guys and St Thomas’ Foundation Trust, King’s College, London, United Kingdom

10. Department of Dermatology, University of Rochester Medical Center, Rochester, New York

11. Regeneron Pharmaceuticals, Inc, Tarrytown, New York

12. Sanofi Genzyme, Cambridge, Massachusetts

13. Sanofi, Bridgewater, New Jersey

14. Sanofi, Chilly-Mazarin, France

Publisher

American Medical Association (AMA)

Subject

Dermatology

Link

https://jamanetwork.com/journals/jamadermatology/articlepdf/2757721/jamadermatology_worm_2019_oi_190062.pdf

Reference32 articles.

1. Therapeutic pipeline for atopic dermatitis: end of the drought?;Paller;J Allergy Clin Immunol,2017

2. Atopic dermatitis.;Weidinger;Lancet,2016

3. Atopic dermatitis.;Bieber;N Engl J Med,2008

4. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes.;Macdonald;Proc Natl Acad Sci U S A,2014

5. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice.;Murphy;Proc Natl Acad Sci U S A,2014

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis;Journal of Allergy and Clinical Immunology: Global;2024-02

2. Efficacy and safety of the regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin (REZPEG) in the treatment of inflammatory skin diseases including atopic dermatitis;2024-01-26

3. Dose tapering of dupilumab in patients with persistently controlled atopic dermatitis: a Spanish multicenter cohort study;International Journal of Dermatology;2024-01-16

4. Considerations for managing elderly patients with atopic dermatitis;Expert Review of Clinical Immunology;2024-01-09

5. Early intervention and disease modification in atopic dermatitis—the current state of the field and barriers to progress;Journal of the European Academy of Dermatology and Venereology;2023-12-08